In vivo expression of antibodies: the coming of age of a further antibody drug modality
Vectorized antibodies by in vivo expression of DNA or RNA overcome limitations of systemically administered antibodies
STUTTGART, Germany I August 30, 2025 I Antibodies as a drug modality in general have become extremely successful in terms of clinically effective therapies and of market size. The global market size of all branded therapeutic antibodies in 2024 reached more than US$ 278 bln. The therapeutic antibody market showed a continuous annual growth rate of 13.1% over the last decade, not only by sales growth of individual antibody therapeutics, but also by the relentless addition of new antibody products.
Nevertheless, systemically administered therapeutics antibodies have limitations including the high cost, caused in great part by manufacturing and control, and the amount of drug needed for repeated administrations at high doses. Development of the manufacturing process as well as commercial scale GMP manufacturing of antibodies in great amounts is a complex process. Other limitiations refer to the inconvenience of frequent administrations associated with an unsatisfactory pharmacokinetic profile, challenging administration procedures to the eye (e.g. subretinal injection) or the central nervous system (e.g. intrathecal infusion with indwelling catheter) or side effects and limited efficacy upon systemic administration without tissue specificity, an important aspect in cancer therapy.
La Merie Publishing has performed a landscape analysis of in vivo expressed, i.e. vectorized, antibodies regarding stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective.
The report “Vectorized antibodies by in vivo expression of DNA or RNA: a competitive business, stakeholder, technology and pipeline analysis from an industry perspective” report brings you up-to-date with information about and analysis of:
- Stakeholders: companies with technologies in viral DNA, oncolytic virus DNA, non-viral DNA and RNA; service providers and biopharmaceutical partners;
- Coroporate profiles of stakeholders: technology, territory, year of foundation, employees, financial situation and highest R&D stage
- Partnerships of vectorized antibody technology companies and biopharmaceutical companies;
- Vectorized antibody technologies; viral DNA, oncolytic virus DNA, non-viral DNA (plasmid, molecular formulation, cellular delivery) and RNA;
- Compositions of vectorized antibody product candidates: DNA or RNA, delivery method and route of administration;
- Pipeline of vectorized antibodies: in ophthalmology, oncology, neurology, infectious disease and other therapeutic areas;
- Clinical experience in safety and efficacy with vectorized antibodies;
- Molecular, preclinical and clinical profile of vectorized antibodies;
- Competitor analysis.
Vectorized antibodies hold promise to overcome many of these limitations and provide a great opportunity for DNA and RNA technology companies to enter larger markets compared with the rare disease indications for which current gene therapies are approved or in development.
The report “Vectorized antibodies by in vivo expression of DNA or RNA: a competitive business, stakeholder, technology and pipeline analysis from an industry perspective” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/vectorized-antibodies-by-in-vivo-expression-of-dna-or-rna-a-competitive-business-stakeholder-technology-and-pipeline-analysis-from-an-industry-perspective/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.
Among La Merie Publishing’s services are the pre-scoped evaluation of customer-selected targets for drug discovery: Target Evaluation for Drug Discovery: Pre-Scoped Premium Evaluation.
SOURCE: La Merie Publishing